This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Tositumomab

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 2: Line 2:
{| class="wikitable" border="1" width="60%" style="text-align:center"
{| class="wikitable" border="1" width="60%" style="text-align:center"
|-
|-
-
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
+
! colspan="5" align="center"| Anti-CD20 Monoclonal Antibody [[Pharmacokinetics]] <ref>GlaxoSmithKline: Study No.: Hx-CD20-402</ref>
|-
|-
! Parameter
! Parameter
Line 10: Line 10:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Tmax|T<sub>max</sub>]] (hr)
+
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
! Tositumomab
! Tositumomab
! 7.6
! 7.6
Line 16: Line 16:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)
+
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
! Tositumomab
! Tositumomab
! 167000
! 167000
Line 22: Line 22:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
+
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab
Line 28: Line 28:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
! 64.8
! 64.8
! 68
! 68
Line 34: Line 34:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
! Tositumomab
! Tositumomab
! 32939000
! 32939000
Line 40: Line 40:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
+
! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h)
! .078
! .078
! .017
! .017
Line 46: Line 46:
! Ibritumomab
! Ibritumomab
|-
|-
-
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
! Tositumomab
! Tositumomab
! Ofatumumab
! Ofatumumab

Revision as of 16:57, 12 December 2010

Pharmacokinetics

Anti-CD20 Monoclonal Antibody Pharmacokinetics [1]
Parameter Tositumomab Ofatumumab Rituximab Ibritumomab
Tmax (hr) Tositumomab 7.6 Rituximab Ibritumomab
Cmax (ng/ml) Tositumomab 167000 205800 Ibritumomab
Bioavailability (%) Tositumomab Ofatumumab Rituximab Ibritumomab
T1/2 (hr) 64.8 68 206 Ibritumomab
AUC (ng/ml/hr) Tositumomab 32939000 Rituximab Ibritumomab
Clearance (L/h) .078 .017 .009 Ibritumomab
IC50 (nM) Tositumomab Ofatumumab Rituximab Ibritumomab
Dosage Tositumomab 500 mg (4th Infusion) 325 mg/m2 (4th Infusion) Ibritumomab
Metabolism Tositumomab Ofatumumab Rituximab Ibritumomab

Proteopedia Page Contributors and Editors (what is this?)

David Canner

Retrieved from "http://52.214.119.220/wiki/index.php/Tositumomab"
Personal tools